Xechem International Inc. - XKEMQ.PK changing it to XKEM.PK - 500 Beiträge pro Seite

[montamero]

Form 8-K for XECHEM INTERNATIONAL INC

17-Oct-2011

Other Events

Item 8.01 Other Events

Change of trading Symbol
On October 7, 2011, the 'Q' was removed from the trading symbol of XKEMQ.PK changing it to XKEM.PK. The "Q" designation is used to indicate reorganization under the Bankruptcy Code. On August 24, 2011, all right, title, and interest to any and all assets of Xechem International, Inc. (the "Company") and Xechem, Inc. where sold at auction, including any and all right, title and interest to Xechem (India) Pvt. Limited and Xechem Pharmaceuticals Nigeria Limited. For further information, see case no. 08-30512 in the United States Bankruptcy Court, Northern District of Illinois (Eastern Division).

Xechem International, Inc. and Ministry of Health, Federal Republic of Nigeria. In July 2002 the Company formed Xechem Pharmaceuticals Nigeria Limited ("Xechem Nigeria"). On July 18, 2002, the Company signed an exclusive worldwide license agreement (the "Agreement") with the National Institute of Pharmaceutical Research and Development (Federal Ministry of Health) the Federal Republic of Nigeria, for the manufacture, marketing, distribution and sales of NIPRISAN(TM), a botanical (the "Botanical") for the treatment of Sickle Cell Disease. The Minister of Health, A.B.C. Nwosu, signed the Agreement in his capacity as Minister of Health of Nigeria.

The Agreement stated there were "�related patents and foreign counterpart patents thereof, and totaling forty-six (46) patents world-wide�.", and the Licensor warranted that "� LICENSED PATENTS are, each and every one, valid and enforceable in their respective jurisdictions, and that LICENSOR has maintained and shall maintain the validity and enforceability of the said PATENT RIGHTS for the term of this AGREEMENT."

Documents filed during the Bankruptcy proceedings of the Company disclosed licensed patents had been abandoned, and were no longer valid and enforceable, before the Agreement was signed on July 18, 2002, and therefore there were not "forty-six (46) patents world-wide" , as the Agreement stated, when the Agreement was signed on July 18, 2002. The Company paid licensing fees and royalty payments to the National Institute of Pharmaceutical Research and Development, and the Company invested substantial sums of money in the development of the Botanical, all under written representations contained in the Agreement signed by The Minister of Health, A.B.C. Nwosu, in his capacity as Minister of Health of Nigeria.

[montamero]

Hier der Link zum 8k von gestern

http://biz.yahoo.com/e/111017/xkem.pk8-k.html
http://finance.yahoo.com/q?s=XKEM.PK

[mani40]

Antwort auf Beitrag Nr.: 42.224.835 von montamero am 18.10.11 11:11:52

sieht so aus als wenn Xechem nur noch ein leerer aber insolvenzfreier Mantel sei?

die Frage ist nur ob uns die Auktion auch ins Geld gebracht hat?


oder wie seht ihr das?

[montamero]

Antwort auf Beitrag Nr.: 42.234.674 von mani40 am 19.10.11 23:58:58

Nein, kein Geld, aber xkem ist nun schuldenfrei.
Swift kaufte Xechem für schlappe 49100$
Monty hat auch mitgeboten, ging aber leer aus.
Bin gespannt wie es mit den Patenten weitergeht...

[montamero]

www.Xechem.com

Change of trading Symbol
On October 7, 2011, the ‘Q’ was removed from the trading symbol of XKEMQ.PK changing it to XKEM.PK. The "Q" designation is used to indicate reorganization under the Bankruptcy Code. On August 24, 2011, all right, title, and interest to any and all assets of Xechem International, Inc. (the “Company”) and Xechem, Inc. where sold at auction, including any and all right, title and interest to Xechem (India) Pvt. Limited and Xechem Pharmaceuticals Nigeria Limited. For further information, see case no. 08-30512 in the United States Bankruptcy Court, Northern District of Illinois (Eastern Division).

Xechem International, Inc. and Ministry of Health, Federal Republic of Nigeria.
In July 2002 the Company formed Xechem Pharmaceuticals Nigeria Limited ("Xechem Nigeria"). On July 18, 2002, the Company signed an exclusive worldwide license agreement (the “Agreement”) with the National Institute of Pharmaceutical Research and Development (Federal Ministry of Health) the Federal Republic of Nigeria, for the manufacture, marketing, distribution and sales of NIPRISAN(TM), a botanical (the “Botanical”) for the treatment of Sickle Cell Disease. The Minister of Health, A.B.C. Nwosu, signed the Agreement in his capacity as Minister of Health of Nigeria.

The Agreement stated there were “…related patents and foreign counterpart patents thereof, and totaling forty-six (46) patents world wide….”, and the Licensor warranted that “… LICENSED PATENTS are, each and every one, valid and enforceable in their respective jurisdictions, and that LICENSOR has maintained and shall maintain the validity and enforceability of the said PATENT RIGHTS for the term of this AGREEMENT.”

Documents filed during the Bankruptcy proceedings of the Company disclosed licensed patents had been abandoned, and were no longer valid and enforceable, before the Agreement was signed on July 18, 2002, and therefore there were not “forty-six (46) patents world-wide” , as the Agreement stated, when the Agreement was signed on July 18, 2002. The Company paid licensing fees and royalty payments to the National Institute of Pharmaceutical Research and Development, and the Company invested substantial sums of money in the development of the Botanical, all under written representations contained in the Agreement signed by The Minister of Health, A.B.C. Nwosu, in his capacity as Minister of Health of Nigeria.

Xechem International, Inc. and Xechem, Inc. Complete Chapter 7, all assets were sold at auction on August 24, 2011.

[montamero]

Speculative interpretations and dissertation on XKEM.

The Big Question:

As of late, as we all sit lying awake at night, hoping and praying for Nigerian approval of Xechem's SCD drug, Nicosan, many questions have been asked from one stock board to another about XKEM and its relationship to Marjorie Chassman and, as well, the validity of XKEM itself. Who is this woman? Is she some ultra-rich financier who has a steadfast head for investing large sums of money into indebted biotech companies in an era when biotech has long since passed its peak? Is she richer and smarter than the world's banking industry itself? Can her financing actually enable the smaller investors to predict the future? The short answer is, no.

Along with all the other XKEM hype, Marjorie Chassman begs the biggest question of them all: Looking into the near future, if Xechem is such an incredible company with so much promise that (as shareholder board posts would have one believe) it simply cannot be denied, then why cannot this company, over the course of so many years (since its inception in the early 90s) acquire real loans from real banks to be paid back with real profits? And why must XKEM look to such "generous" individuals as Margie Chassman for a majority of its loan structure/value, while continuing to increase its float and reverse split, since before and after the turn of the century?

One answer and one name: DAVID BLECH

Has anyone ever heard of the famously coined phrase, "Blech Thursday"?
It was a phrase coined in the early/mid 90s that came to symbolize the end of the biotech era as it was once known.
And David Blech's name is synonymous with that end.

David Blech was an upstart and ambitious venture capitalist who sprung essentially from nowhere (he was a songwriter and 'entrepreneur') in the late 80s with $10,000 in his pocket and big dreams. He started multiple companies in the biotech industry and a few years later was worth over the hundred million dollar mark. (Bristol Meyers bought one of his companies, Genetech Systems, for $294 million only later to do their own DD, find out its true value was practically zilch, and sell it away for a paltry $20 million -- "taking a $274 million dollar bath") http://www.findarticles.com/p/articles/mi_m1316/is_n8_v21/ai…

Long story short, (you can do the DD yourself with the links i've provided and with everything else that's out there), but upon the collapse of the biotech boom, Blech was eventually filed suit against by numerous private and public companies, individuals, class-action suits and, of course, the SEC. Longer story shorter: he plead guilty to a mass of charges brought against him and/or plead out and eventually turned 'informant' on those he'd conspired with in exchange for leniency by the Feds.

So, how XKEM found the ever-generous Marjorie Chassman to loan them all this money (millions upon millions) over so many years while the company showed nothing but debt has but one best guess: through David Blech.
How'd that come to be you may ask? Simple... Chassman and Blech are married.

As the Seattle Times reported: at the onset of his downfall, when Blech's first wife discovered he was forging her signature for false purposes, she divorced him immediately. His second wife, Marjorie Chassman, was reported to be "a graphic designer and aspiring actress" who was supporting him at the time of his demise. http://seattletimes.nwsource.com/uninformed_consent/financie…

So, again, it begs the question: How would his second wife, Marjorie Chassman (a graphic designer and aspiring actress) have the know-how and savvy to get involved in the vast and complicated world of loaning indebted companies millions and trading in public securities to great personal gain (of which thus far i have found 3: NVLT.OB, CEPO.OB and SCLL.OB). Answer: Through her husband and "partner-in-speculatively-questionable-activity", David Blech.

And, guilty as charged, David Blech is (squirm) involved in XKEM and may very well be the leader of this big parade.

Direct Link between XKEM and BLECH: http://www.littleindia.com/archive/dec96/survive.htm
Excerpt: "On Nov 19 (1996-ish), Xechem announced that a group controlled by David Blech, a well-known but controversial investor in the biotechnology industry, will invest $5.5 million in the company over the next nine months. As a result of the deal, Blech and his associates will replace Pandey as Xechem's controlling shareholders, with a stake of more than 70 percent. Pandey, however, will remain the CEO as well as the second-largest shareholder. He is delighted at the deal because the capital infusion will allow Xechem to develop products that he believes could become big winners in the future. "With Blech's investment and expertise, our future is very bright," he says. "In the next three to five years, we could have sales of $30 million to $50 million.""

Those sales predictions came in 1996 for the future of 1997. Well, we all know that didn't happen as the loans continue today and XKEM continues to show massive losses.

Note XKEM / Chassman / Blech link:
While many on the boards are speaking zealously how the debt owed by XKEM will not have to be paid until 2008, please note the paragraph below from this link: http://biz.yahoo.com/e/050623/xkem.ob8-k.html
Excerpt: "For the period from November 11, 2003 through June 30, 2004, Marjorie Chassman, the spouse of David Blech ("Chassman") advanced $2,800,000 of convertible debt to Xechem, which debt accrued approximately $320,884 in interest (as of June 20, 2005) and is due and payable December 31, 2006, subject to the required sale of Xechem's holdings of CepTor Stock."
(the CepTor deal is an entirely other issue)
Blech's shady past:
http://www.bearstearnsfraudinfocenter.com/information.php
Excerpt: "The case was a $77 million class action lawsuit filed against Bear Stearns on behalf of investors who claimed they had lost their money due to the fraudulent actions of David Blech, a Bear Stearns client. The judge stated that a summary judgment could not be made because there were not enough facts available to determine if Bear Stearns was guilty or not. Bear Stearns said that it had no knowledge of Blech’s stock manipulating (he pled guilty to charges of fraud in 1999). The investors who lost their money to Blech want to convince the jury otherwise."

Link demonstrating Chassman/Blech relationship:
http://freeadvice.brand.edgar-online.com/EFX_dll/EDGARpro.dl… essionID=qYy_S2bI2EM...
Excerpt: "In January 2005, we entered into an agreement with David Blech (the husband of Margie Chassman), which provided that he or his designees would lend us $500,000 (inclusive of $100,000 previously advanced to us in December 2004 by Ms. Chassman) for operating capital pending our debt restructuring and completion of our private placements of units, and up to an additional $500,000 on the same terms if the private placement was delayed.... The two loans, both of which were made by Ms. Chassman, totaled $500,000 and bore interest at 6% per annum.... According to the agreement, we also issued the following individuals the following number of shares of our common stock:


Investor

Number of Shares
of Common stock
Margie Chassman


2,475,000

Wood River Trust


3,850,000

Esther Blech


1,225,000

Milton Chassman


1,225,000

Aaron Eiger


1,225,000

Mark Germain


500,000


Wood River Trust is a trust formed for the benefit of Evan Blech, the son of Ms. Chassman and Mr. Blech. The trustees of the trust are Harvey Kesner and Michael C. Doyle (no relation to our director, Michael J. Doyle). Esther Blech is the mother-in-law of Ms. Chassman. Milton Chassman is the brother of Ms. Chassman. These investors have agreed not to publicly sell their shares of common stock until November 2006 and if they sell their shares in a private transaction, the buyer must also agree not to sell their shares publicly until November 2006."

(The whole family's in on that one!)

Other companies who are involved with Chassman and Blech also have troubling outlooks:
--In mid-August of 2005 NVLT.OB (another Chassman/Blech involved company) was at $4.47 a share. Today, it's worth .95c.
--In mid-February of 2005 CEPO.OB (another Chassman/Blech involved company) was at $6.75 a share. Today, it's worth .24c.

How did Blech do it? http://www.sec.gov/news/digest/02-07.txt
Excerpt: "From approximately June through September 1994, David Blech, the chief executive officer of D. Blech & Co., orchestrated a massive manipulative scheme designed to increase or stabilize the prices of a number of the biotechnology securities for which D. Blech & Co. was a market maker. As part of this scheme, David Blech routinely sold biotechnology stocks from D. Blech & Co.'s inventory accounts to brokerage accounts that Blech controlled that were in the names of other individuals and entities. These controlled accounts then sold the biotechnology stocks back to the brokerage firm or to other accounts controlled by David Blech. These trades created the appearance of active trading in the biotechnology stocks. Additionally, through this trading, Blech was able to reduce D. Blech & Co.'s inventory position in the biotechnology stocks, yet still artificially withhold from the market the supply of the biotechnology stocks."

So, with XKEM, how many shares of this roughly 1.3 billion O/S count do we all REALLY own? Long. For Real. No Flipping? Your guess is as good as mine.

The most recent official audit I was able to find was released in 2003 and noted the following:
Excerpt from: http://yahoo.brand.edgar-online.com/EFX_dll/EDGARpro.dll?Fet… nID=rQRcI4St_vooX3Y&...

REPORT OF INDEPENDENT ACCOUNTANTS
To the Audit Committee of Xechem International, Inc.
We have audited the accompanying consolidated balance sheet of Xechem International, Inc. and Subsidiaries (a Development Stage Company) as of December 31, 2002 and the related consolidated statements of operations, stockholders' equity and cash flows for the period ended December 31, 2002. The consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the consolidated financial statements based on our audit.
We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statements presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Xechem International, Inc. and Subsidiaries (a Development Stage Company) as of December 31, 2002 and the consolidated results of their operations and their consolidated cash flows for the period ended December 31, 2002 in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred substantial losses and negative cash flows since inception through the period ended December 31, 2002, had a working capital deficiency, and have realized minimal revenues to date. The Company's historical losses and illiquid financial position raise substantial doubt about the Company's ability to continue as a going concern.
WISS & COMPANY, LLP ?Livingston, New Jersey ?March 6, 2003

While that audit is a few years old, it essentially predicted XKEM's true future and present condition at this time. Leaving nothing said of the begging questions of XKEM, Margie Chassman and David Blech's relationship and Blech's shady past, there's definitely more to this story than I've uncovered and certainly much more that will never be told.

So why go through all the trouble and take such HUGE risks on an indebted company with a very questionable future? There's millions of reasons (literally). One speculative scenario: Get in at the beginning and loan a company money that you know can't pay you back (resulting in consistently debt-ridden quarterly public financial statements) in exchange for huge amounts of shares (often times valued at far lower than the current PPS) and SHORT, SHORT, SHORT, in which case after the inevitable reverse splits come (3000:1 in XKEM's case in May of '03) and an ever-increasing float bears down on shareholders, those who have put themselves in a short position stand to make nearly incalculable gains. Bear this in mind: XKEM's initial IPO was $5 a share and it went as high as $13. It's now doing everything it can to stay above .03.

Other companies who are currently involved with Chassman and Blech also have troubled outlooks:
--In mid-August of 2005 NVLT.OB (another Chassman/Blech involved company) was at $4.47 a share. Today, it's worth .98c.
--In mid-February of 2005 CEPO.OB (another Chassman/Blech involved company) was at $6.75 a share. Today, it's worth .20c.

I'm not here to bash, and I'm certainly not telling you to buy or sell. Simply stated, as we all look forward to the apparent 'emminent' day when Nigerian approval becomes transparent, this is the information I have discovered while checking into whether or not XKEM would be worth a "true investment" on my behalf, and not just a daily 'flip' for a quick few hundred bucks.

This stock will come and go, just like the rest of them. And no doubt, Nigerian approval could do vast wonders for the immediate PPS (ie. CRDM and others), but stocks such as XKEM though must always remain a reminder that: "If it's too good to be true, then it probably is."
GLTA,

This post is strictly 'in my opinion' and is interpretation only of the details listed in links provided above (among others), historical data, research and my own overall DD. Do not trade based on my opinions. DO YOUR OWN DD!

[montamero]

Neue Nicosan Formel durch Robert Swift:

Novel botanical formulation (old Nicosan) for treating sickle cell disease - New Patent (20110300242) through Swami Nathan and Robert Swift

- It's the new Nicosan with an other solvent ph used for extraction (sodium bicarbonate ph 8-8,3)
- new formulation: 8 % of cells still sickled
- Nicosan: 18 % of cells still sickled
- Filed Date: 8. Jun. 2010
- Published Date: 8. Dec. 2011

http://www.freepatentsonline.com/20110300242.pdf

[montamero]

http://sec.gov/litigation/suspensions/2012/34-66297.pdf

[montamero]

http://dailytrust.com.ng/index.php?option=com_content&view=a…

[montamero]

Xechem - Grey Market
...und es wird weiter gehandelt, seit einer Woche wurden ca. 8m gekauft, ... keine Verkäufe.
Vielleicht ist da noch was im Busch mit Swift und seinen neuen Patenten.
Swift hat sich ja Nicosan jetzt endgültig unter den Nagel gerissen.

[montamero]

http://www.wipo.int/patentscope/search/en/WO2011146471

5-HMF - Xechem - Ch.11 - AesRX-COS-103 - R. Swift

[montamero]

Technical Chart Shows Upside on XECHEM INTL INC

Im in shock!XECHEM INTL INC is on the verge of a major change in trend. Check out this site

goo.gl/jvrxA


http://finance.yahoo.com/mbview/threadview/?&bn=2cd4bb83-e6b…

http://freestockchartanalysis.info/" target="_blank" rel="nofollow ugc noopener">http://freestockchartanalysis.info/

LOL
GLTA!

[montamero]

Seht euch mal Ilns an!!!

[montamero]

Antwort auf Beitrag Nr.: 43.618.355 von montamero am 18.09.12 20:37:15

Falls an diesem "spam" vom Yahoo board was dran sein sollte dann müßte Xkem zuerst wieder zum Handel zugelassen werden.... alles ist möglich.

In der Zwischenzeit +%% täglich mit Intellect Neuroscience [ILNS].

[montamero]

Lonza and Intellect Neurosciences Announce Intellect’s Intention to Award Production of its Antibody Drug Conjugate, CONJUMAB-A


New York (USA) and Basel (Switzerland), 27 September 2012 – Lonza announced today that Intellect Neurosciences, Inc. (OTCBB:ILNS) awarded the future development and manufacture of the antibody drug conjugate CONJUMAB-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s CONJUMAB-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease. Intellect Neurosciences is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.

The new program is expected to include in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza. Intellect also plans to work with a number of independent specialized contract research organizations to evaluate the compounds produced by Lonza Chemical Manufacturing in Visp, Switzerland. Intellect‘s program is led by Dan Shochat, Ph.D., Intellect Neurosciences’ Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.

"CONJUMAB-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We anticipate improved efficacy compared to naked amyloid beta antibodies currently in clinical development for AMD. The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences, and we are very proud to be working with such a high caliber team at Lonza," said Dr. Daniel Chain, Chairman and CEO. "Based on recent discussions with global pharmaceutical companies that have expressed interest in the program, we see this program as a near-term opportunity for potential partnering for Intellect."

"Lonza looks forward to collaborating with Intellect Neurosciences on its CONJUMAB-A program," said Stefan Stoffel, Head of Lonza Chemical Manufacturing. "We have already generated a detailed road map for the optimization and manufacture of CONJUMAB-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

http://finance.yahoo.com/news/lonza-intellect-neurosciences-…


http://www.wallstreet-online.de/diskussion/1173897-31-40/int…

http://investorshub.advfn.com/Intellect-Neurosciences-Inc-IL…

[reitenhammer999]

hallo was denn jetzt los mit dem laden, ist der jetzt pleite und man kann die dinger abschreiben, oder kommt da noch was

[Dragon68]

Hallo,

hat jemand ne Ahnung was hier Stand ist ?